Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E1105.44 EPS (ttm)0.06 Insider Own0.11% Shs Outstand1.26B Perf Week-1.05%
Market Cap80.77B Forward P/E9.30 EPS next Y6.78 Insider Trans-0.82% Shs Float1.25B Perf Month-3.95%
Income123.00M PEG394.66 EPS next Q2.02 Inst Own79.80% Short Float1.85% Perf Quarter4.96%
Sales24.69B P/S3.27 EPS this Y-97.70% Inst Trans-0.47% Short Ratio2.58 Perf Half Y-3.45%
Book/sh14.48 P/B4.35 EPS next Y-5.27% ROA0.20% Target Price74.11 Perf Year-16.43%
Cash/sh5.78 P/C10.90 EPS next 5Y2.80% ROE0.60% 52W Range56.56 - 85.97 Perf YTD8.15%
Dividend2.84 P/FCF19.85 EPS past 5Y-61.80% ROI5.00% 52W High-26.71% Beta0.42
Dividend %4.51% Quick Ratio1.30 Sales past 5Y-5.40% Gross Margin81.50% 52W Low11.40% ATR1.45
Employees13600 Current Ratio1.40 Sales Q/Q26.20% Oper. Margin16.50% RSI (14)43.78 Volatility2.09% 2.10%
OptionableYes Debt/Eq1.73 EPS Q/Q-42.80% Profit Margin0.50% Rel Volume0.76 Prev Close62.46
ShortableYes LT Debt/Eq1.57 EarningsFeb 04 AMC Payout- Avg Volume8.97M Price63.01
Recom2.40 SMA20-3.29% SMA50-0.23% SMA200-5.26% Volume6,836,285 Change0.88%
Jan-19-21Upgrade Morgan Stanley Equal-Weight → Overweight $83
Jan-04-21Upgrade Guggenheim Neutral → Buy
Nov-03-20Resumed Morgan Stanley Equal-Weight $67
Oct-28-20Initiated UBS Neutral $61
Sep-30-20Resumed Jefferies Buy $78
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Mar-02-21 05:21PM  
01:24PM  
Mar-01-21 02:58PM  
01:45PM  
Feb-25-21 02:39PM  
02:13PM  
11:26AM  
10:20AM  
Feb-23-21 06:55AM  
Feb-18-21 10:35AM  
10:15AM  
08:01AM  
Feb-17-21 04:17PM  
11:40AM  
Feb-16-21 04:05PM  
02:45PM  
10:30AM  
Feb-15-21 11:59PM  
Feb-11-21 03:28PM  
09:13AM  
08:25AM  
07:14AM  
Feb-10-21 05:15PM  
02:52PM  
11:57AM  
11:10AM  
09:00AM  
06:25AM  
Feb-08-21 12:13PM  
08:00AM  
Feb-06-21 07:30AM  
Feb-05-21 03:29PM  
11:07AM  
10:37AM  
10:00AM  
07:15AM  
06:00AM  
05:42AM  
01:31AM  
Feb-04-21 07:44PM  
05:55PM  
05:25PM  
04:55PM  
04:25PM  
04:13PM  
04:05PM  
04:02PM  
04:01PM  
02:45PM  
01:47AM  
Feb-03-21 07:00PM  
10:14AM  
Feb-02-21 08:00AM  
Feb-01-21 04:21PM  
08:13AM  
06:17AM  
06:00AM  
04:10AM  
Jan-31-21 02:19AM  
Jan-29-21 04:32PM  
10:34AM  
09:39AM  
Jan-28-21 05:45PM  
12:31PM  
Jan-27-21 06:14AM  
Jan-25-21 05:00PM  
Jan-24-21 08:53AM  
Jan-23-21 06:08AM  
Jan-22-21 06:48AM  
Jan-21-21 04:01PM  
01:30PM  
01:57AM  
01:01AM  
Jan-20-21 01:43PM  
Jan-19-21 04:11PM  
01:50PM  
01:35PM  
09:31AM  
08:00AM  
Jan-18-21 07:00AM  
Jan-16-21 11:17PM  
Jan-15-21 05:45PM  
Jan-14-21 02:36PM  
Jan-13-21 02:11PM  
05:51AM  
Jan-12-21 04:31PM  
03:26PM  
03:18PM  
08:00AM  
Jan-11-21 03:39PM  
11:20AM  
10:32AM  
10:21AM  
09:22AM  
08:25AM  
06:24AM  
06:00AM  
Jan-08-21 09:11AM  
Jan-07-21 05:45PM  
Jan-06-21 10:26AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wilfong Diane E.SVP, Controller & CAOFeb 10Option Exercise0.00778017,606Feb 11 05:58 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale67.411,975133,13528,832Feb 11 05:56 PM
Wilfong Diane E.SVP, Controller & CAOFeb 06Option Exercise0.001,866017,361Feb 09 07:46 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise0.002,728031,560Feb 09 07:44 PM
Dickinson Andrew DEVP, Chief Financial OfficerFeb 06Option Exercise0.001,818033,081Feb 09 07:41 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 01Sale65.979,711640,63328,832Feb 03 06:23 PM
Lofton Kevin EDirectorJan 22Option Exercise20.6520,282418,72274,203Jan 25 01:55 PM
Whitley Richard JamesDirectorOct 01Option Exercise0.001,434031,122Oct 05 07:09 PM
Parsey MerdadChief Medical OfficerAug 17Sale68.3218212,4340Aug 19 12:53 PM
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM